ArticleMolecules (Basel, Switzerland)2026
Eugenol-Based Epoxy Vitrimers: Caffeine and Zinc Acetate as Potential Alternative Catalysts in Curing Kinetics and Dynamic Network Properties.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The development of sustainable vitrimers from bio-based sources addresses the need for high-performance recyclable materials. This research describes eugenol-derived epoxy vitrimers cross-linked with adipic acid as a curing agent, focusing on comparative effects of caffeine and zinc acetate as transesterification catalysts at 5 and 10% concentrations versus a non-catalyzed control. Both catalysts acted as curing accelerators, confirmed by FTIR and DSC analyses, revealing polyhydroxyester network formation through associative ester exchange enabling topological reorganization. Zinc acetate at 10% proved most efficient, achieving the lowest apparent activation energy (116.0 kJ/mol), highest crosslinking density (ν
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.